New Paradigm for Non-selective Beta-blockers in Cirrhosis
Article Sidebar
Main Article Content
Abstract
Portal hypertension is an imperative pathophysiology in cirrhosis and results in several complications, especially esophageal varices. Non-selective beta-blockers (NSBBs) are effective for decreasing portal hypertension, a significant amount of relevant evidence points to their efficacy for reducing bleeding in high-risk varices as well as variceal rebleeding. Recent study has demonstrated that NSBBs are beneficial for preventing decompensation in cirrhosis with clinically significant portal hypertension. Therefore, this article reviewed existing and updated indications, including appropriate use of NSBBs in cirrhosis.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: evidence-based indications and limitations. JHEP Rep [Internet]. 2019[cited 2021 June 30];2(1):100063. Available from: https://doi.org/10.1016/j.jhepr.2019.12.001
Zacharias AP, Jeyaraj R Hobolth L, Bendtsen F, Gludd LL, Morgan MY. Carvedilol versus traditional, non-selective beta-blocker for adults with cirrhosis and gastroesophagealvarices. Cochrane Database Syst Rev [Internet].2018 [cited 2021 June 30];10:CD011510. Available from: https://doi.org/10.1002/14651858.cd011510.pub2
Sinagra E, Perricone G, D’Amico M, Tine F, D’Amico G. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment PharmacolTher 2014;39:557–68.
Jachs M, Hartl L, Schaufler D, Desbalmes C, Simbrunner B, Eigenbauer E, et al. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut 2021;70:1758-67.
Gimenez P, Garcia-Martinez I, Francés R, Gonzalez-Navajas JM, Mauri M, Alfayate R, et al. Treatment with non-selective beta blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis. Liver Int 2018;38:2219-27.
Thiele M, Albillos A, Abazi R, Wiest R, Gluud LL, Krag A. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomised trials. Liver Int 2015;35:2009-16.
Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastro- esophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-61.
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65:310-35.
deFranchis R. Expanding consensus in portal hypertension: Report of the Baveno VI consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743-52.
Qi XS, Bao YX, Bai M, Xu WD, Dai JN, Guo XZ. Nonselective beta-blockers in cirrhotic patients with no or small varices: a meta analysis. World J Gastroenterol 2015;21:3100-8.
Bhardwaj A, Kedarisetty CK, Vashishtha C, Bhadoria AS, Jindal A, Kumar G, et al. Carvedilol delays the progression of small oesophagealvarices in patients with cirrhosis: a randomized placebo-controlled trial. Gut 2017;66:1838-43.
D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475-505.
Gludd LL, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophagealvarices in adults. Cochrane Database Syst Rev [Internet] 2012 [cited 2021 Jun 30];8:CD004544. Available from:https://doi.org/10.1002/14651858.cd004544.pub2
Mishra SR, Sharma BC, Kumar A, Sarin SK. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomised controlled trial. J Hepatol 2011;54:1161-7.
Hung HH, Chang CJ, Hou MC, Liao WC, Chan CC, Huang HC, et al. Efficacy of non-selective beta-blockers as adjunct to endoscopic prophylactic treatment for gastric variceal bleeding: a randomized controlled trial. J Hepatol 2012;56:1025-32.
Villanueva C, Albillos A, Genesca J, Garcia-Pagan JC, Calleja JL, AracilC, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomized, double-blind, placebo-controlled, multicentre trial. Lancet 2019;393:1597–1608.
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII-Renewing consensus in portal hypertension. J Hepatol 2022;76:959-74.
Bang UC, Benfield T, Hyldstrup L, Jensen JB, Bendtsen F. Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. Liver Int 2016;36:1304-12.
Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology [Internet]. 2014[ cited 2021June 30]; 146(7):1680-90.e1
Yang J, Ge K, Chen L, Yang JL. The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective beta-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of varicealrebleeding: a meta-analysis. Eur J Gastroenterol Hepatol 2019;31:1518-26.
Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. ClinMol Hepatol 202;27:425-36.
Ferrusquía-Acosta J, Bassegoda O, Turco L, Reverter E, Pellone M, Bianchini M, et al. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. J Hepatol 2021;74:811-8.